Simnova Raises Nearly RMB 400 Million in Series B Financing to Advance CAR-NK and In Vivo CAR-T Platforms
Shanghai-based cell therapy developer Simnova has completed a nearly RMB 400 million (approximately US$55 million) Series B financing round, providing fresh capital to advance its lead off-the-shelf CAR-NK program SNC103 and its emerging in vivo CAR-T…
AusperBio Raises $120 Million Series C to Advance AHB-137 Toward Hepatitis B Functional Cure and Commercialization
AusperBio has raised $120 million in Series C financing to advance its lead chronic hepatitis B therapy AHB-137 through Phase III development and prepare for potential commercialization, while expanding a next-generation pipeline of siRNA and combination…
DAJO Bio Raises Tens of Millions of RMB in Seed Financing to Advance Next-Generation TCR Protein Therapies
Shenzhen-based biotechnology startup DAJO Bio (“DAJO”) has completed a seed financing round worth tens of millions of RMB, providing fresh capital to advance its next-generation T-cell receptor (TCR) protein therapeutic platforms and pipeline…
Navi Therapeutics raises Series A to advance AI-driven next-generation ADC platform
China-based biotech Navi Therapeutics (Shanghai) Co., Ltd. (“Navi”) has completed a Series A financing round, marking the company’s second fundraising since its founding roughly 18 months ago and bringing its cumulative funding to…
iRegene secures another 260 million yuan in Series C+ financing to accelerate pipeline development
On July 2nd, iRegene Therapeutics announced the completion of a RMB 260 million Series C+ financing round. This round was led by Chengdu Science and Technology Venture Capital, with participation from CITIC Securities Capital, Xichuan Venture Capital,…
MagicRNA raises hundreds of millions of yuan in Series B financing to advance world’s first in vivo CAR-T therapy
Recently, Shenzhen MagicRNA Biotechnology Co., Ltd. (or MagicRNA) announced the completion of a Series B financing round of several hundred million yuan. This round was led by a fund under CICC Capital, co-led by Kangjun Capital , with participation from…
Hopstem completes nearly 200 million yuan Series C financing to accelerate its core iPSC programs.
On August 10, 2026, Zhejiang Hopstem Biotechnology Co., Ltd. (or Hopstem) announced the completion of the first tranche of its nearly RMB 200 million Series C financing. This round of financing was jointly participated in by new shareholders Tasly…
Xgene secured RMB 250 million in series D financing to develop novel non-opioid analgesic drugs
Recently, Xgene Pharmaceutical Inc. (“Xgene”), a company focusing on the research and development of innovative drugs in the fields of pain and neurology, completed a RMB 250 million Series D financing round. This round was jointly led by Yifeng…